What is ImmuneOnco Biopharmaceuticals (Shanghai) Accounts Receivable?
Accounts Receivable are created when a customer has received a product but has not yet paid for that product. ImmuneOnco Biopharmaceuticals (Shanghai)'s accounts receivables for the quarter that ended in Dec. 2023 was HK$0.04 Mil.
Accounts receivable can be measured by Days Sales Outstanding.
ImmuneOnco Biopharmaceuticals (Shanghai)'s Days Sales Outstanding for the quarter that ended in Dec. 2023 was 23.93.
In Ben Graham's calculation of Net-Net Working Capital, accounts receivable are only considered to be worth 75% of book value. ImmuneOnco Biopharmaceuticals (Shanghai)'s Net-Net Working Capital per share for the quarter that ended in Dec. 2023 was HK$1.41.
ImmuneOnco Biopharmaceuticals (Shanghai) Accounts Receivable Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's accounts receivables are being managed.
ImmuneOnco Biopharmaceuticals (Shanghai)'s Days Sales Outstanding for the quarter that ended in Dec. 2023 is calculated as:
2. In Ben Graham's calculation of Net-Net Working Capital (NNWC), ImmuneOnco Biopharmaceuticals (Shanghai)'s accounts receivable are only considered to be worth 75% of book value:
ImmuneOnco Biopharmaceuticals (Shanghai)'s Net-Net Working Capital Per Share for the quarter that ended in Dec. 2023 is calculated as:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
Net receivables tells us a great deal about the different competitors in the same industry. In competitive industries, some attempt to gain advantage by offering better credit terms, causing increase in sales and receivables.
If company consistently shows lower % Net receivables to gross sales than competitors, then it usually has some kind of competitive advantage which requires further digging.
Average Days Sales Outstanding is a good indicator for measuring a company's sales channel and customers. A company may book great revenue and earnings growth but never receive payment from their customers. This may force a write-off in the future and depress future earnings.
ImmuneOnco Biopharmaceuticals (Shanghai) Accounts Receivable Related Terms
Thank you for viewing the detailed overview of ImmuneOnco Biopharmaceuticals (Shanghai)'s Accounts Receivable provided by GuruFocus.com. Please click on the following links to see related term pages.
ImmuneOnco Biopharmaceuticals (Shanghai) (HKSE:01541) Business Description
ImmuneOnco Biopharmaceuticals (Shanghai) Inc is a science-driven biotechnology company dedicated to the development of immuno-oncology therapies. It is one of the few biotechnology companies globally adopting a systematic approach to harness both the innate and adaptive immune systems. It has developed a rich pipeline of 14 drug candidates with eight ongoing clinical programs, featured by a comprehensive innate-immunity-based asset portfolio. Its pipeline reflects its extensive understanding of the frontiers of cancer biology and immunology and its expertise in turning scientific research into drug candidates.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
HKSE:01541 has been successfully added to your